STAT+: Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
Eli Lilly on Wednesday said that its investigational drug was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study, further boosting the competitive profile of its medicine. In the head-to-head study, people on the highest dose of Lilly’s…






